¡°	administer metaxalone	33.59603765521916
¡°	metaxalone therapy	33.49555983597373
¡°	muscle relaxant metaxalone	22.668811816919373
¡°	patient metaxalone	22.370934305482496
¡°	patient receive metaxalone	16.77828625761091
¡°	metaxalone bioavailability	13.817274407763048
¡°	Skelaxin	5.343189084883536
	food consumption	3.6889466159737054
	Albanese	3.55839085483703
	Metaxalone	2.972602181772466
	Ngai	2.967616968429749
	Abrams	2.671594542441768
	food increase bioavailability	2.4616245490459203
	Cmax	2.3789164534256204
	AUC(last	2.3789164534256204
	Fathie II	2.0814819883104496
	specific food condition	1.7504215913482428
	milk	1.3722219089119077
	Labs Inc. motion	1.2704904331370932
	attempt	1.22746246228267
	meal	1.1952859736824426
	Musculoskeletal Conditions	1.1900851375940587
	Dent	1.1894582267128102
	painful musculosketal condition	1.112505590639462
	Acute Musculoskeletal Disorders	0.9036001244699675
	CLINICAL MEDICINE	0.8928252128115667
	instructional limitation	0.8924743565736043
	CLINICAL DRUG THERAPY	0.7936689145215876
	nausea	0.7176752751548231
	oral bioavailability	0.7109213706018491
	registered nurse	0.7021341939271106
	curiam	0.686593112699398
	A.H. Robins Company Inc. A.H. Robins	0.6807384346874689
	controversy	0.6210621378089201
	fathie II	0.596350754278956
	KAZEM FATHIE	0.5953563179416292
	albanese	0.5953563179416292
	JR	0.5953563179416292
	Abstract].	0.5951475189488431
	drug bioavailability	0.5521867224112821
	gastric upset	0.45554650886800246
	gastric discomfort	0.3975893244546741
	JOSEPH ALBANESE	0.39747322278523795
	Affirmed	0.34341726541603
	Placebo	0.34341726541603
	maximal plasma concentration	0.3215661728424737
	NURSES drug REFERENCE	0.3184933195227818
	Bridgewood Servs	0.30499370396232284
	Cooperative Study	0.2945913677545649
	gastrointestinal distress	0.2807155277110673
	absorption	0.2425812856332665
	Dependent	0.23939330346401674
	Kappos	0.23939330346401674
	Chakrabarty	0.23939330346401674
	New Relaxant	0.19887350425495995
	unstated limitation	0.1984970246141167
	therapeutically effective amount	0.19243449982914573
	single tablet dosage	0.18449422828491968
	Bioavailability	0.171708632708015
	corporation	0.16968286443268374
	tablet form	0.15043423898783206
	dosage amount	0.1441326018774819
	dosage limitation	0.14334709059921533
	preamble-"a method	0.11949736196931202
	unclean hand	0.11945642777985652
	ICU Med	0.11567862538340695
	alteration	0.11051333550871768
	therapeutically effective range	0.1099111833635142
	Paragraph IV Certification	0.09636257857690568
	dosage range	0.09596849599432673
	invalidated	0.09070787014609129
	novelty	0.08721821897376288
	print information	0.08007374469562993
	several patient	0.07602220605958279
	print label	0.07595127570557934
	two hour	0.07580553422293508
	oral dosage form	0.07346244551650455
	cautionary notice	0.06923115921694575
	Legal Standards	0.06683467209235536
	jurisdictional argument	0.06624296280788068
	jurisdictional fact	0.06624237061735917
	unit dosage form	0.06230298394254663
	wherein administration	0.056258663226108487
	Development	0.05035717490231932
	aff'd sub nom	0.049719144152766064
	Treatment	0.04969924595115271
	fraud	0.046499824840729606
	inherent disclosure	0.03917883964266511
	physical phenomenon	0.03907721885885213
	management	0.03671717503125632
	vague condition	0.0341571248575246
	ten consecutive day	0.033456722521274664
	certain percentage increase	0.030179174925410283
	inherent property	0.02803174617777177
	ANDA	0.02589932642700354
	Gajarsa	0.025312908415222685
	blood stream	0.01825233459349925
	abstract idea	0.015807638065602723
	thirty seven	0.015369074565131303
	name brand version	0.01440725385010041
	solely inform limitation	0.01296584356253827
	Hatch Waxman Act	0.012736003905698984
	pharmaceutical composition	0.012728196842380699
	justifiable inference	0.01234023220734845
	Plaintiff	0.01186029038434879
	specific condition	0.010936305993477882
	another reference guide	0.010609719028939894
	precise condition	0.010405158536528849
	certification	0.010077964151685142
	current therapeutic research	0.010023317744652331
	another entity	0.00995928760806808
	clinical study	0.009850469425065293
	invalidity counterclaim	0.009752535535057947
	moot	0.009112391077480221
	extent	0.00766901548589737
	instruction sheet	0.007215998402596305
	timing limitation	0.006939735624506417
	attorney fee	0.006456876504047206
	various time frame	0.0063540063671779405
	anticipation	0.0062718638066621615
	particular machine	0.005602421530063774
	Abbreviated New Drug Application	0.005519800639541244
	Liberty Lobby	0.0054472871004801705
	human subject	0.005295919319579819
	rate	0.004735316890916243
	anticipate	0.004154696818721054
	affirmative defense	0.004100083795033661
	exclusive test	0.003838430386757075
	New York grant	0.003660681600118165
	i.	0.0035785734713001936
	actual case	0.0032792094751100146
	apparatus	0.003044924519145183
	variation	0.0025173896005132815
	six prior art reference	0.0023385525919906425
	sale	0.0023158536429065597
	commercial success	0.0021058075112153165
	Eastern District	0.001924148133693394
	complaint	0.001889594160266781
	non movant favor	0.00177196507634634
	a.	0.001707032472455242
	holder	0.0016949323147034624
	interest	0.001693747468553301
	nature	0.0016415340791405392
	June	0.0016259580278434782
	nonobviousness	0.0015545702662930708
	unexpected finding	0.0014906547544336621
	know compound	0.0014830881328976543
	Federal Circuit motion panel	0.0014417613110256312
	none	0.001401853416383291
	objective indication	0.00137074274823145
	August	0.0012716502779432858
	January	0.0012698992775830172
	patentability	0.0009323742867847046
	R.Civ	0.0008978696932516069
	source	0.0008752358969883249
	July	0.0008132648715451324
	particular article	0.0008079003795304586
	expert report	0.0007933177335036537
	April	0.0007740300075184448
	earlier state reason	0.0007672782636338659
	defendant	0.0006488692918588287
	three independent	0.0005288216355743915
	early related action	0.0005198904643848455
	initial matter	0.000518437426698108
	write description	0.000479419741522589
	four	0.0003935569593346537
	asserted	0.00035058658313343955
	patented product	0.0003474590869988909
	Sys	0.00028600233524998586
	genuine issue	0.00028483678021489276
	summary judgment proceeding	0.0002787960381602934
	P.	0.00025840642479355984
	broad term	0.00021241946730808005
	prior owner	0.000210847204113977
	nothing	0.00019998296151753201
	third party	0.0001935360458617777
	specific time	0.0001902520738812282
	summary judgment de novo	0.0001795749917892971
	additional limitation	0.0001714385260473411
	Claim	0.00016309043909629327
	entire	0.00015729295778928477
	lack	0.00015611513337188249
	summary judgment opinion	0.0001555004744794982
	summary judgment order	0.00015238636376452462
	write material	0.00014670077217182237
	invalidity determination	0.00014398100820433958
	invalidity judgment	0.00014284792279315857
	subject matter jurisdiction	0.00010200862227038153
	every limitation	9.943368292530106e-05
	even disclosure	9.517736976176452e-05
	prior art disclosure	9.483418107004133e-05
	holding	8.801682630557719e-05
	response	7.60186658592329e-05
	district court invalidity order	7.325853362806686e-05
	final judgment	7.180385328196645e-05
	suit	6.111484497372196e-05
	background	5.712374982683556e-05
	Ltd.	3.941739290353967e-05
	remain	2.9338942101859062e-05
	three reference	2.6109188356643823e-05
	single prior art reference	2.577931674388304e-05
	know product	2.282839181155859e-05
	ordinary skill	1.8875835293929976e-05
	language	1.7702757899146322e-05
	testimony	1.5136069313876037e-05
	l.ed.2d	1.0237939378306657e-05
	material fact	5.103152632165365e-06
	emphasis	4.912503042479152e-06
	different state	4.8674220831242436e-06
	light	2.9393934059565237e-06
	Idaho	1.4444108686614848e-06
	district court grant	8.63279135645603e-07
	present appeal	3.468227193315147e-07
	law	9.13728035840857e-08
	first	1.7482313092532564e-08
	district court judgment	1.1218499060785331e-08
	invention	2.300739170663737e-09
	U.S. District Court	7.332878584919862e-10
	Appeals	0.0
